Maturitas
Volume 55, Issue 3 , Pages 219-226 , 20 October 2006

Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women

  • Simona Mencej

      Affiliations

    • University of Ljubljana, Faculty of Pharmacy, Chair of Clinical Biochemistry, Aškerčeva cesta 7, SI-1000 Ljubljana, Slovenia
    • ,
  • Janez Preželj

      Affiliations

    • University Clinical Centre, Department of Endocrinology and Metabolic Diseases, Zaloška cesta 2, SI-1000 Ljubljana, Slovenia
    • ,
  • Andreja Kocijančič

      Affiliations

    • University Clinical Centre, Department of Endocrinology and Metabolic Diseases, Zaloška cesta 2, SI-1000 Ljubljana, Slovenia
    • ,
  • Barbara Ostanek

      Affiliations

    • University of Ljubljana, Faculty of Pharmacy, Chair of Clinical Biochemistry, Aškerčeva cesta 7, SI-1000 Ljubljana, Slovenia
    • ,
  • Janja Marc

      Affiliations

    • University of Ljubljana, Faculty of Pharmacy, Chair of Clinical Biochemistry, Aškerčeva cesta 7, SI-1000 Ljubljana, Slovenia
    • Corresponding Author InformationCorresponding author. Tel.: +386 1 4769600; fax: +386 1 4258031.

Received 31 August 2005 ,Revised 3 March 2006 ,Accepted 7 March 2006.

References 

  1. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-B ligand and osteoprotegrin in bone cell biology. J Mol Med. 2001;79:243–253
  2. Miyamoto T, Suda T. Differentiation and function of osteoclasts. Keio J Med. 2003;52(1):1–7
  3. Lacey DL, Timms E, Tan HL, et al. Osteoprotegrin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–176
  4. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–179
  5. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegrin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–319
  6. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegrin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145:527–538
  7. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188:997–1001
  8. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95:3597–3602
  9. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315–323
  10. HUGO Gene Nomenclature Committee, Homepage, http://www.gene.ucl.ac.uk/nomenclature/ (accessed April 11, 2005).
  11. Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of RANKL (receptor activator of NKκB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999;25:525–534
  12. Walsh MC, Choi Y. Biology of TRANCE axis. Cytokine Growth Factor Rev. 2003;14:251–263
  13. Kitazawa R, Kitazawa S, Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochem Biophys Acta. 1999;1445:134–141
  14. O’Brien CA, Kern B, Gubrij I, Karsenty G, Manolagas SC. Cbfa1 does not regulate RANKL gene activity in stromal/osteoblastic cells. Bone. 2002;30:453–462
  15. Roccisana JL, Kawanabe N, Kajiya H, Koide M, Roodman GD, Reddy SV. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem. 2004;12:10500–10507
  16. Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM. The ratio of messenger RNA levels of receptor activator of nuclear factor κB ligand to osteoprotegrin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res. 2001;16:1015–1027
  17. Tsangri H, Findlay DM, Kuliwaba JS, Atkins GJ, Fazzalari NL. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of femoral neck. Bone. 2004;35:334–342
  18. Walker S, Finch MB, Marsh D, Li G. In postmenopausal women, femoral neck BMD is positively correlated to circulating levels of soluble RANKL and negatively correlated to levels of IL-7. J Bone Miner Res. 2004;19(Suppl 1):M397
  19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988;16:1215
  20. Hsu Y, Niu T, Terwedow H, et al. Variation in genes involved in the RANKL/RANK/OPG bone remodelling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet. 2006;118:568–577
  21. Kitazawa S, Kitazawa R. Epigenetic control of mouse receptor activator of NF-κB ligand gene expression. Biochem Biophys Res Commun. 2002;290:650–655

PII: S0378-5122(06)00093-4

doi: 10.1016/j.maturitas.2006.03.004

Maturitas
Volume 55, Issue 3 , Pages 219-226 , 20 October 2006

Article Tools

* Image Usage & Resolution